Targeting heart muscle cells to improve heart function in cardiomyopathy
Cardiomyocyte selective modulation of natriuretic peptide signaling in cardiomyopathy
This project looks for new ways to protect heart muscle cells and improve heart function for people living with cardiomyopathy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11135425 on NIH RePORTER |
What this research studies
Many people with cardiomyopathy still face a high risk of heart failure and sudden death, even with current treatments. Existing medications can have side effects and don't always target specific heart cells. This project explores new strategies to specifically adjust signals within heart muscle cells, aiming to reduce the progression of heart disease and prevent sudden death. By focusing on these specific cells, we hope to develop more effective and targeted therapies.
Who could benefit from this research
Good fit: Patients living with cardiomyopathy who are at risk for heart failure and sudden death could potentially benefit from future therapies developed from this work.
Not a fit: Patients without cardiomyopathy or those whose condition is not related to natriuretic peptide signaling may not receive direct benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to new, more targeted treatments that reduce heart failure progression and prevent sudden death in patients with cardiomyopathy.
How similar studies have performed: Previous research has shown that preventing the breakdown of certain heart-protective peptides can significantly improve outcomes for patients with dilated cardiomyopathy, though current approaches can have side effects.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Becker, Jason — University of Pittsburgh at Pittsburgh
- Study coordinator: Becker, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.